A look at upregulated targets outside of the BCR signalling pathway and what small molecules are looking promising

In our final preview of ASH 2020 exploring key abstracts and what to watch out for this weekend, we offer the second half of our discussion around small molecules in early stage development.

There’s always a roller coaster ride in any early stage drug development and small molecule inhibitors are no different from antibodies, bispecifics, or even immunotherapies in this respect.

There are certainly some unexpected and surprising overlaps discussed and uncovered here plus also some novel combination approaches either being considered or which may potentially need to be considered in the future.

So what’s in store this time around?

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH meeting — including our final Preview ahead of the meeting this weekend, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by